Ypsomed Holding AG · SIX:YPSN

Ypsomed — FY2005/06 Earnings Presentation

53 slides from Ypsomed's earnings presentation, May 30, 2006

  1. Slide 1: Presentation of 2005/06 Annual Results

    Presentation of 2005/06 Annual Results Solothurn, 30th May 2006

  2. Slide 2: Important Notice

    Important Notice The information contained in this document has not been independently verified and no representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein.

  3. Slide 3: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 3

  4. Slide 4: Share Price Development

    Share Price Development Share Price Development (22 September 2004 - 26 May 2006) 240 31.3.2006 220 200 180 160 CHF 140 31.3.2005 120 100 80 60 22. Sep 04 22. Nov 04 22. Jan 05 22. Mrz 05 22. Mai 05 22. Jul 05 22. Sep 05 22. Nov 05 22. Jan 06 22. Mrz 06 22. Mai 06 Ypsomed SPI Index (Rebased) 4

  5. Slide 5: Ypsomed Highlights 2005/06

    Ypsomed Highlights 2005/06 Sales up 28.4% from CHF 241.8 million to CHF 310.6 million. Steep growth of 44.7% in core business with pen systems and pen needles Operating profit margin increased to 20.1%. Net income improved by 42% from CHF 39.2 million to CHF 55.6 million Profit per share reached CHF

  6. Slide 6: 206 additional jobs created in 2005/06

    206 additional jobs created in 2005/06 1139 933 97 797 116 560 141 118 1042 Total Europe + 237 + 136 817 + 206 656 442 Total CH 31.03.2003 31.03.2004 31.03.2005 31.03.2006 6

  7. Slide 7: Sales Growth in Core Business of 44.7%

    Sales Growth in Core Business of 44.7% CHF million 2005/06 2004/05 in % Sales of goods and services 310.6 241.8 28.4% Ypsomed finished products 269.6 186.4 44.7% FreeStyle* 3.5 20.7 -83.1% Other products 37.5 34.8 7.8% Previous year adjusted for FreeStyle 310.6 224.9 38.1% *Abbott took over the excl

  8. Slide 8: EBIT-Margin increased to 20.1%

    EBIT-Margin increased to 20.1% CHF million 2005/06 2004/05 in % Sales of goods and services 310.6 241.8 28.4% Gross profit 119.2 96.9 23.0% Gross margin (%) 38.4 40.1 Operating profit (EBIT) 62.3 47.5 31.1% EBIT margin (%) 20.1 19.7 Net profit 55.6 39.2 42.0% Net profit margin (%) 17.9 16.2 8

  9. Slide 9: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 9

  10. Slide 10: Strong sales growth and improved profitability

    Strong sales growth and improved profitability CHF million 2005/06 in % 2004/05 in % in % Sales of goods and services 310.6 100.0% 241.8 100.0% 28.4% Cost of goods and services sold -191.4 -61.6% -144.9 -59.9% 32.0% Gross profit 119.2 38.4% 96.9 40.1% 23.0% R & D reimbursed 5.6 1.8% 6.0 2.5% -6.1% R

  11. Slide 11: Net Profit improved by 42%

    Net Profit improved by 42% CHF million 2005/06 in % 2004/05 in % in % Operating profit (EBIT) 62.3 20.1% 47.5 19.7% 31.1% Financial income 4.3 1.4% 2.1 0.9% 101.0% Financial expense -2.1 -0.7% -4.1 -1.7% -47.2% Other income/(expense) -0.1 0.0% 0.0 0.0% -255.6% Profit before taxes 64.4 20.7% 45.7 18.

  12. Slide 12: EBITDA remained at 28.7%

    EBITDA remained at 28.7% CHF million 2005/06 in % 2004/05 in % in % Operating profit 62.3 20.1% 47.5 19.7% 31.1% Amortization of intangible assets 1.0 0.3% 0.8 0.3% 30.6% Depreciation of fixed assets 25.7 8.3% 21.0 8.7% 22.1% EBITDA 89.0 28.7% 69.4 28.7% 28.4% 12

  13. Slide 13: Cash Flow Statement

    Cash Flow Statement CHF million 2005/06 2004/05 in % Cash flow before changes in NWC 85.5 69.2 23.5% Changes in net working capital -28.3 25.6 Cash flow from operating activities 57.2 94.8 -39.7% Cash flow from investing activities -41.3 -66.4 -37.8% Changes in marketable securities 29.9 -70.0 Chang

  14. Slide 14: Advance Payments of OEM Partners

    Advance Payments of OEM Partners thereof machinery CHF million 2005/06 of OEM partners Cash flow before changes in NWC 85.5 Changes in net working capital -28.3 -14.5 Cash flow from operating activities 57.2 -14.5 Purchases of fixed assets -40.1 -14.5 1) Disposals of fixed assets 0.7 14.5 1) Purchas

  15. Slide 15: Balance Sheet

    Balance Sheet CHF million 31.03.2006 in % 31.03.2005 in % Cash and cash equivalents 65.7 9.9% 56.0 8.5% Marketable securities 41.2 6.2% 69.6 10.6% Trade receivables 45.4 6.8% 39.6 6.0% Other current assets 10.9 1.6% 7.3 1.1% Inventory 44.1 6.6% 34.6 5.3% Total current assets 207.3 31.1% 207.1 31.4%

  16. Slide 16: Equity Ratio of 60.7%

    Equity Ratio of 60.7% CHF million 31.03.2006 in % 31.03.2005 in % Trade payables 23.7 3.6% 41.6 6.3% Current income taxes payable 5.7 0.9% 5.4 0.8% Other payables and accr. expenses 18.4 2.8% 18.4 2.8% Total current liabilities 47.8 7.2% 65.5 9.9% Non-current finan. liab. to shareholder 200.0 30.0%

  17. Slide 17: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 17

  18. Slide 18: New Pen-Systems since 2004

    New Pen-Systems since 2004 OptiClik® for Lantus OptiClik® for Apidra Gonal-f ® pen Preos-Pen (Nycomed/NPS) Symlin YpsoPen for Insulin 18

  19. Slide 19: Update on Production Capacity

    Update on Production Capacity Production capacity for OptiSet® and OptiClik® have been massively expanded during the last 24 months. The OptiSet® production has been more than doubled last year and is currently operated in 4 shifts (24 hours / 7 days per week). Current demand for OptiClik® is bigger

  20. Slide 20: Novo suit against Sanofi-Aventis unjustified

    Novo suit against Sanofi-Aventis unjustified On 2nd September 2005 and May 2006 Novo Nordisk filed patent infringement suits against our customer Sanofi-Aventis in the USA in connection with the OptiClik® pen. Internal and external expert assessment concluded that the OptiClik® pen does not infringe

  21. Slide 21: Outlook: Guidance for 2006/07

    Outlook: Guidance for 2006/07 Sales growth forecast of 10% to 15% Current delivery levels of OptiClik® are lower than anticipated due to manufacturing. Sales for the 2006/07 business year are therefore expected to increase by between 10% and 15% with a weaker first half and a stronger second half ye

  22. Slide 22: Outlook: 2006/07 Sales Guidance of 10% to 15%

    Outlook: 2006/07 Sales Guidance of 10% to 15% CHF in millions 450 IPO Guidance 400 of +25% range 2006/07 Guidance: 350 +10% to +15% 3.5 300 IPO Guidance 37.5 of +15% range 250 20.7 200 34.8 46.3 150 21.8 269.6 36.2 100 17.4 10.2 186.4 10.2 130.6 50 90.8 73.0 0 2001/02 2002/03 2003/04 2004/05 2005/06

  23. Slide 23: Investing in Intellectual Property

    Investing in Intellectual Property Ypsomed invested CHF 22.8 million in research & development Ypsomed via TecPharma Licensing AG manages over 150 patent families Strategic initiative launched for new proprietary technology Priority Applications per Annum Granted Patents by Region 31 32 32 35 28 30

  24. Slide 24: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 24

  25. Slide 25: Ypsomed's Growth Strategy

    Ypsomed‘s Growth Strategy Ypsomed is the technology leader and number one independent manufacturer of injection systems worldwide. Ypsomed’s strategy is focused to maintain and expand its position in the future. In order to achieve this objective, Ypsomed will… Expand and improve production capacity

  26. Slide 26: Diabetes - Key Market for Ypsomed's Growth

    Diabetes - Key Market for Ypsomed’s Growth Diabetes market growing at more than 3% worldwide Insulin market growing at more than 10% and expected to grow at this rate for the next 10 years Lantus growing at more than 40% - Q1/06 growth of 42% Apidra being launched in the US and other countries 26

  27. Slide 27: Diabetes – Worldwide Epidemic Disease

    Diabetes – Worldwide Epidemic Disease year 2000 2030 Ranking Country People with diabetes (millions) 1 India 31.7 79.4 + 150% 2 China 20.8 42.3 + 103% 3 USA 17.7 30.3 + 71% Source: WHO Spring 2006 27

  28. Slide 28: Lantus – Leading long-acting Insulin

    Lantus – Leading long-acting Insulin Lantus is a long-acting insulin How Lantus® works with a save and smooth insulin action profile. Major advantage of Lantus: only once daily administration. Graph: sanofi-aventis 28

  29. Slide 29: Growth Factor Lantus

    Growth Factor Lantus Worldwide Lantus Sales Lantus is the worldwide leading long- acting insulin and one of sanofi-aventis’ blockbusters. +47.5%* +110.0%* 84 Lantus was first launched in 2000 in Germany, followed by the USA in 2001, 413 England in 2002 and France in 2003. +40.5%* 41 Lantus since the

  30. Slide 30: Market Share of Lantus has risen steeply

    Market Share of Lantus has risen steeply Who initiated insulin therapy NRx share of Lantus® in total insulin among new insulin patients? market: PCPs 88% 35% Lantus®, 32% 30% 70% Premix, 27% 25% Mealtime, 26% 20% 15% NPH, 14% 10% 16% 5% 4% 0% J u -03 Se -0 3 J u -0 4 Se -0 4 S -0 5 Ju -05 PCPs Endoc

  31. Slide 31: Insulin Pen Penetration to Increase in USA

    Insulin Pen Penetration to Increase in USA Successful launch of OptiClik® in the US for Lantus and Apidra. US market today with low insulin pen penetration rate of ~15%. Lantus sales in the US in 2005 were up 46.6% to reach € 717m. Thereof about 80% was still sold in conventional vials. Competition

  32. Slide 32: Ypsomed's Partnership with Sanofi-Aventis

    Ypsomed‘s Partnership with Sanofi-Aventis The partnership between Ypsomed and Sanofi-Aventis (formerly Aventis and Hoechst) has been ongoing for 20 years. Ypsomed has become a strategically important supplier of Sanofi-Aventis for its blockbuster insulin Lantus and other insulins. Sanofi-Aventis wil

  33. Slide 33: Growth Potential of Lantus and Pen Systems

    Growth Potential of Lantus and Pen Systems Lantus expected to grow in sales over € 3 billion Sales with pen systems to increase from current levels of estimated 40% to grow to over 90% within the next 10 years. Sales w/o Pens Sales in Pens 2003 2005 2007 2009 2011 2013 2015 Source: Ypsomed estim. 33

  34. Slide 34: Growth Potential for Ypsomed with Lantus

    Growth Potential for Ypsomed with Lantus Today, 100% of pen systems are delivered by Ypsomed. Sanofi-Aventis has publicly announced to need 1 million pens per day in the future to satisfy strong market demand for Lantus, Apidra and other insulins. Sales w/o Pens Other Pens Ypsomed Pens 2003 2005 200

  35. Slide 35: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 35

  36. Slide 36: Questions & Answers

    Questions & Answers YPS©MED SELFCARE SOLUTIONS aby 36

  37. Slide 37: Important Dates

    Important Dates Key reporting dates Presentation of Annual Results 2005/06 May 30, 2006 Annual Shareholder Meeting June 27, 2006 in Burgdorf Half Year Report November 9, 2006 Selected Congresses (pen & diabetes business) 18. - 21.06.2006 AAPS National Biotechnology Meeting in Boston 14. - 17.09.2006

  38. Slide 38: Agenda

    Agenda Presentation of the Annual Results 2005/06 Highlights 2005/06 Financials 2005/06 Outlook Strategy going forward Questions and Answers Additional Information on company and products 38

  39. Slide 39: Key facts about Ypsomed

    Key facts about Ypsomed Largest independent medical technology manufacturer for injection devices for pharmaceutical and biotech companies. One of the leading manufacturer and suppliers of pen needles. Global headquarter in Burgdorf, Switzerland; manufacturing facilities in Burgdorf, Solothurn, Gren

  40. Slide 40: Company Background

    Company Background Injection Systems Business Infusion Systems Business Self Injection Devices Infusion Systems Pen Needles Continuous Glucose Monitoring Blood Glucose Monitoring Blood Glucose Monitoring 40

  41. Slide 41: Corporate Structure

    Corporate Structure Ypsomed Holding AG (Burgdorf) Ypsomed AG Ypsotec AG TecPharma Licensing AG (Burgdorf/Solothurn) (Grenchen) (Burgdorf) Ypsotec s.r.o (Czech Republic) Ypsomed GmbH Ypsomed BV Ypsomed AB Ypsomed SAS (Germany) (Netherlands) (Sweden) (France) DiaExpert GmbH (Germany) 41

  42. Slide 42: Ypsomed benefits from multiple growth factors

    Ypsomed benefits from multiple growth factors Market & Sales Growth New Plattform Technology Auto-Injectors Reusable Pens (Semi-) Disposable Pens Pen Needles Self-Medication Trend New Biotech Compounds Long-acting Insulin Diabetes & Insulin Emerging Countries Sedentary Lifestyle Ageing Population Dr

  43. Slide 43: Overview of Products and Applications

    Overview of Products and Applications Ypsomed’s activities are organized in three business sectors: Self Injection Devices Pen Needles Diabetes Care (OEM Business) Development and Development and Local access to manufacturing of custom- manufacturing of pen customers and opinion made self-injection

  44. Slide 44: Overview of Pharma Partnerships

    Overview of Pharma Partnerships Insulin hGH interferon & EPO 44

  45. Slide 45: Overview of Pharma Partnerships

    Overview of Pharma Partnerships r-hFSH r-PTH Symlin ... and other partners 45

  46. Slide 46: Product Overview

    Product Overview Getting away from it all … Cumbersome and painful injection Needle phobia … to convenience and simplicity … to reliance and accuracy … to increased compliance Pens (reusable or disposable or semi-disposable) … to successful therapy Auto-Injectors 46

  47. Slide 47: Injection pen needles

    Injection pen needles Penfine® - Universal Pen Needle Fits all major brands of pens on the market Maximum handling convenience: Click- or twist-on, twist-off (Glue-free, welded construction) Largest range available: 6 mm x 31G 8 mm x 31G 10 mm x 29G 12 mm x 29G Patented click-on mechanism 47

  48. Slide 48: New Biotech Applications

    New Biotech Applications With the increase of biotech products, the proportion of injectable drugs will rise over time 15% 11% 13% 13% 12% 38% 35% 44% 58% 66% 50% 53% 42% 27% 24% Marketed Filed Phase III Phase II Phase I Injection Oral Other Source: Evaluate Pharma. Includes only products where deli

  49. Slide 49: Main Self-Injection Markets

    Main Self-Injection Markets 49

  50. Slide 50: Disposable Fixed Dose Pen

    Disposable Fixed Dose Pen Features: Fixed dose Smallest dose / dose increment: 20 l Gearing to reduce injection force Simple and easy handling with pull – push principle Clear user feedback for ' dose setting completed' ,'injection stroke completed' 50

  51. Slide 51: Disposable Variable Dose Pen with Dose Memory

    Disposable Variable Dose Pen with Dose Memory Features: Dose memory Smallest dose 10 l Gearing to reduce injection force Simple and easy handling with pull – push principle 51

  52. Slide 52: Disposable Auto-Injector

    Disposable Auto-Injector Features: Fully disposable the most convenient way to deliver single fixed dose injections For 1 ml long pre-filled syringes, customization for other syringe types possible Shortest device on market (130 mm) Needle hidden throughout entire injection process Irreversibly lock

  53. Slide 53: Reusable Auto-Injector for Safety Syringes

    Reusable Auto-Injector for Safety Syringes Features: Specifically designed for SSI' s Ultra-Safe® Passive Delivery Systems Dry-firing of power-pack not possible Interlock: firing button can only be pushed when device is pressed against skin Two-stage injection process: drug deliver starts only after

Ypsomed Holding — FY2005/06 Earnings Presentation on 6ix